Clinical Development & Data
Trial architecture, endpoints, recruitment, comparator signals, investigator interpretation, and the way evidence in cardiovascular & pulmonary vascular will be read downstream.
Cardiovascular & Pulmonary Vascular
ICG works across cardiovascular and pulmonary vascular environments where clinical positioning, specialist pathways, long-term outcomes, reimbursement, delivery, and commercial organization must be read as one system.
The work includes cardiovascular competitive intelligence, PAH development and launch assessment, anticoagulant and lipid-market analysis, access pathways, delivery systems, field organization, and longitudinal portfolio monitoring.
Chronic Systems. High-Consequence Transitions.
Cardiovascular and pulmonary vascular decisions sit across evidence, guidelines, specialist networks, diagnostic thresholds, chronic treatment behavior, hospital pathways, and payer interpretation.
ICG reconstructs how those elements shape adoption and competitive position, including the points at which a clinical signal becomes a formulary, pathway, account, or field-organization decision.
Decision Environments
Engagements begin at different points, but the governing constraints often cross the boundaries of the initial request.
Regulatory & Access Pathways
Filing logic, label conditions, evidence requirements, reimbursement, pathway position, and country-level adoption constraints.
Launch & Commercial Architecture
Market preparation, field-force and medical roles, account coverage, channel structure, patient support, and launch sequencing.
Manufacturing & Delivery
Capacity, supply, configuration, administration, device or site readiness, and the relationship between operational uncertainty and asset value.
Patient & Treatment Systems
Patient identification, referral patterns, specialist pathways, administration burden, monitoring, persistence, and continuity of treatment.
Longitudinal Competitive Monitoring
Clinical, regulatory, access, organization, and commercial signals reconstructed across multi-phase and multi-year programs.
Evidence Architecture
The evidence base is developed through source calls and interviews positioned close to the decisions, constraints, and operating conditions being reconstructed.
Clinical & Investigator Side
Key opinion leaders, principal investigators, study-site personnel, treating specialists, centers of excellence, diagnostic pathways, and investigator-side clinical teams.
Company-Side Sources
Clinical development, regulatory, medical affairs, CMC and manufacturing, market access, patient services, field leadership, commercial, and portfolio functions.
Access & Operating Systems
Payer and reimbursement environments, procurement, distribution, treatment centers, testing providers, administration systems, patient-support infrastructure, and local access pathways.
Triangulation
Interview evidence is tested against clinical, regulatory, manufacturing, access, and organizational signals and against the criteria used by reviewers, payers, clinicians, partners, and other decision-makers.
Selected Project Record
Selected engagements across cardiovascular & pulmonary vascular.
The projects below are selected from a substantially larger body of work. They were chosen to illustrate different decision environments, lifecycle stages, modalities, geographies, and forms of engagement. The selection is illustrative rather than exhaustive. Multi-phase and longitudinal assignments may be presented as a single project title, and company, asset, or market details may be generalized where appropriate.
Clinical Development & Data
- Trial-Recruitment Assessment for a First-in-Class Therapy in Pulmonary Arterial Hypertension
- Clinical-Development Landscape for PCSK9-Targeted Therapies
- Clinical and Label-Scenario Assessment for Next-Generation Anticoagulants
- Competitive Development Assessment Across Pulmonary-Hypertension Portfolios
Regulatory, Access & Adoption
- European Launch Preparation and Access Assessment for a First-in-Class PAH Therapy
- Reimbursement and Formulary Architecture for Oral Anticoagulants in Europe and Asia
- Market-Access Assessment for Anticoagulants in Germany, Denmark and the United States
- Patient-Identification and Specialist-Referral Architecture in Pulmonary Arterial Hypertension
Launch & Commercial Architecture
- Launch and Field-Organization Assessment for PCSK9-Targeted Therapies
- Field-Force Benchmarking for Anticoagulants in Germany
- Commercial Architecture for Pulmonary-Hypertension Therapies Across Europe
- Launch-Scenario Assessment for a Novel PAH Therapy in Selected European Markets
Manufacturing, Delivery & Systems
- Delivery and Supply Architecture for Prostacyclin Therapies
- Administration-Pathway Assessment for Subcutaneous Pulmonary-Vascular Therapies
- Hospital and Specialist-Center Architecture for Advanced PAH Therapies
- Device and Training Requirements for Chronic Pulmonary-Vascular Treatment
Longitudinal Monitoring & Portfolio
- Continuous Competitive Monitoring of Cardiovascular Portfolios
- Longitudinal Generic-Entry Monitoring Across Bosentan, Iloprost and Epoprostenol Markets
- Multi-Phase Competitive Monitoring Across Pulmonary-Hypertension Therapies
- Longitudinal Market and Launch Monitoring in Dyslipidemia
Cardiovascular & Pulmonary Vascular Engagements
ICG can enter at the level of a single critical question, a multi-market evidence program, or a longitudinal clinical, regulatory, manufacturing, access, commercial, or operating-system decision environment.